CD40LG and complex regional pain syndrome: Given that IV RTX demonstrated analgesic potency in patients with CRPS (Goebel and Blaes, 2013) and anti-myelin-associated glycoprotein (MAG) immunoglobulin M (IgM) demyelinating neuropathy (Dalakas et al., 2009) and has shown efficacy in rat disease models (Novotny et al., 2012; Li et al., 2013; Takahashi et al., 2017), in this study, we used a rat sciatic nerve CCI mononeuropathy model to assess sex differences in MBP epitope release, anti-MBP autoantibody generation, and anti-allodynic potency of IV RTX therapy for a focal PNS trauma.